The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2)
C Delcourt, Y Huang, J Wang, E Heeley, R Lindley, C Stapf, C Tzourio, H Arima, M Parsons, J Sun, B Neal, J Chalmers, C Anderson
INTERNATIONAL JOURNAL OF STROKE | SAGE PUBLICATIONS LTD | Published : 2010
RATIONALE: The INTERACT pilot study demonstrated the feasibility of the protocol, safety of early intensive blood pressure lowering and effects on haematoma expansion within 6 h of onset of intracerebral haemorrhage. This article describes the design of the second, main phase, INTERACT2. AIMS: To compare the effects of a management strategy of early intensive blood pressure lowering with a more conservative guideline-based blood pressure management policy in patients with acute intracerebral hemorrhage. DESIGN: INTERACT2 is a prospective, randomized, open label, assessor-blinded end-point (PROBE). Patients with a systolic blood pressure greater than 150 mmHg and no definite indication for or..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
The management of INTERACT2 includes an ICC based at the George Institute for International Health of the University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia. The study is overseen by an International Executive (Steering) Committee comprised of experts in the fields of stroke, hypertension, neurology, geriatrics, cardiovascular epidemiology and clinical trials. The ICC currently communicates with three RCCs: The George Institute India in Hyderabad (India), The George Institute China in Beijing (China) and the Clinical Research Unit of Lariboisiere Hospital in Paris (France). The ICC and RCCs will communicate with approximately 140 participating hospitals in Africa, Australia, China, several European countries, India, Pakistan, several South American countries and the United States. The study is supported by a Project (512402) and Programme (571281) Grants from the National Health and Medical Research Council (NHMRC) of Australia.